Back to results
US 2023/0390255 A1Published application
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
AssigneeDeciphera Pharmaceuticals, LLC
InventorsMichael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Life of this patent
Estimating the term…
Abstract
Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.
Claims3
A pharmaceutical composition for orally delivering a compound represented by Formula (I):
- the pharmaceutical composition comprising:
- a solid dispersion comprising:
- (a) 50 mg of the compound wherein the compound is present in amorphous form;
- and
- (b) hydroxypropyl methyl cellulose acetate succinate.
2 more elements
A pharmaceutical composition for oral delivery, comprising:
- a solid dispersion comprising:
- (a) an amorphous form of a compound represented by Formula (I):
- and
- (b) hydroxypropyl methyl cellulose acetate succinate.
1 more element
A pharmaceutical composition for oral delivery, comprising:
- (i) a solid dispersion and one or more pharmaceutically acceptable carriers, wherein the solid dispersion comprises:
- (a) an amorphous form of a compound represented by Formula (I):
- and
- (b) hydroxypropyl methyl cellulose acetate succinate.
1 more element
Dependencies are inferred from the claim text.